Form 4: Camp4 Therapeutics Director Steven Holtzman Granted 9,000 Stock Options

Steven H. Holtzman, a Director at Camp4 Therapeutics Corp, was granted 9,000 stock options with an exercise price of $1.56, vesting on the earlier of one year from the grant date or the next annual meeting.

Summary

• Steven H. Holtzman, a Director of Camp4 Therapeutics Corp (CAMP), was granted 9,000 stock options.
• The stock options have an exercise price of $1.56 per share.
• The grant date for these options was June 25, 2025.
• The options vest in their entirety on the earlier of the first anniversary of the grant date (June 25, 2026) or the date of the issuer's next annual meeting of stockholders.
• Vesting is subject to Mr. Holtzman's continued service to the issuer's board of directors through the applicable vesting date.
• The expiration date for these stock options is June 24, 2035.
• Following this transaction, Mr. Holtzman beneficially owns 9,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's interests with the company's long-term performance and shareholder value, indicating continued commitment.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• This is a standard form of compensation for board members, indicating continued commitment from the director.

Future Outlook

This Form 4 filing details a compensation event for a director and does not provide forward-looking statements regarding the company's financial performance or strategic outlook. It indicates the potential for the director to acquire common stock in the future upon vesting and exercise of the options.

Industry Context

The granting of stock options to directors is a common and standard practice in the biotechnology and pharmaceutical industries. It serves as a key component of executive and board compensation, designed to align the interests of leadership with long-term shareholder value creation. This specific transaction is a routine insider compensation disclosure.

Comparison to Industry Standards

• The mechanism of granting stock options to directors is a widely accepted and standard practice across the biotech and broader corporate landscape, aligning director incentives with company performance.
• The vesting schedule, tied to continued service and either a one-year anniversary or the next annual meeting, is typical for director equity grants, ensuring retention and commitment.
• The exercise price of $1.56, while specific to Camp4 Therapeutics, is a common feature of options, allowing the director to benefit from future stock price appreciation above this threshold.

Corporate Governance

Related Party Transactions

• The grant of stock options to Steven H. Holtzman, a director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• Employees: No direct impact on employees is indicated by this specific filing, though it reflects the company's overall compensation philosophy for leadership.

Next Steps

• The stock options will vest on the earlier of June 25, 2026, or the date of the issuer's next annual meeting of stockholders, provided Steven H. Holtzman continues his service on the board.
• Upon vesting, Steven H. Holtzman will have the right to exercise these options at $1.56 per share until their expiration on June 24, 2035.

Key Dates

Keywords

Camp4 Therapeutics, CAMP, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Steven H. Holtzman